down arrow

Boston Scientific Corp.

  • Market Cap: Large Cap
  • Industry: Retailing
  • ISIN: US1011371077
USD
97.72
-0.85 (-0.86%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

97.1599.27

52 Week

85.98109.50
Valuation
Technical
Day's Volume

CASH

9.41 M

Shareholding (Mar 2025)

FII

23.08%

Held by 565 FIIs

DII

38.5%

Held by 179 DIIs

Promoter

0.23%

How big is Boston Scientific Corp.?

22-Jun-2025

As of Jun 18, Boston Scientific Corp. has a market capitalization of $177.29 billion, with recent net sales of $17.55 billion and a net profit of $2.02 billion over the last four quarters.

Market Cap: As of Jun 18, Boston Scientific Corp. has a market capitalization of 177,288.56 million, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Boston Scientific Corp. reported net sales of 17,553.00 million and a net profit of 2,024.00 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 21,770.00 million and total assets of 39,395.00 million.

Read More

What does Boston Scientific Corp. do?

22-Jun-2025

Boston Scientific Corporation develops and markets medical devices for various interventional specialties, with recent net sales of $4.66 billion and a net profit of $672 million. The company has a market cap of approximately $177.29 billion and key metrics include a P/E ratio of 86.00 and a dividend yield of 5,863.88%.

Overview:<BR>Boston Scientific Corporation is a developer, manufacturer, and marketer of medical devices used in various interventional medical specialties, operating within the retailing industry and classified as a large-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4,663 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 672 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 177,288.56 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 86.00 <BR>Dividend Yield: 5,863.88% <BR>Debt Equity: 0.47 <BR>Return on Equity: 9.28% <BR>Price to Book: 7.98<BR><BR>Contact Details:<BR>Address: 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA: 01752-1234 <BR>Tel: 1 508 6834000 <BR>Website: https://www.bostonscientific.com/

Read More

Who are in the management team of Boston Scientific Corp.?

22-Jun-2025

As of March 2022, the management team of Boston Scientific Corp. includes Michael Mahoney (Chairman, President, CEO), Edward Ludwig (Lead Independent Director), and independent directors Nelda Connors, Charles Dockendorff, Yoshiaki Fujimori, and Donna James. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Boston Scientific Corp. includes the following individuals:<BR><BR>- Mr. Michael Mahoney: Chairman of the Board, President, Chief Executive Officer<BR>- Mr. Edward Ludwig: Lead Independent Director<BR>- Ms. Nelda Connors: Independent Director<BR>- Mr. Charles Dockendorff: Independent Director<BR>- Mr. Yoshiaki Fujimori: Independent Director<BR>- Ms. Donna James: Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is Boston Scientific Corp. overvalued or undervalued?

20-Sep-2025

As of July 23, 2025, Boston Scientific Corp. is considered attractive despite a high P/E ratio of 86 compared to peers, due to its strong growth potential and impressive long-term performance, having returned 135.56% over three years, significantly outpacing the S&P 500.

As of 23 July 2025, Boston Scientific Corp. has moved from very expensive to attractive, indicating a significant shift in its valuation perspective. The company appears to be undervalued, especially when considering its P/E ratio of 86, which is notably higher than the peer average P/E of 73.71, and an EV to EBITDA ratio of 44.86 compared to the peer average of 45.38. Additionally, the PEG ratio stands at 6.37, suggesting that the stock may not be priced favorably relative to its earnings growth potential.<BR><BR>In terms of peer comparison, McKesson Corp. has a P/E of 57.25 and Cencora, Inc. has a P/E of 40.09, both of which indicate that Boston Scientific's valuation is higher, yet it is classified as attractive due to its growth prospects. Despite recent underperformance with a 1-week return of -5.86% compared to the S&P 500's 1.05%, the company has shown resilience with a 3-year return of 135.56%, significantly outperforming the S&P 500's 70.41% in the same period, reinforcing its potential for future growth.

Read More

Is Boston Scientific Corp. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Boston Scientific Corp. shows a mildly bearish trend influenced by bearish MACD readings and Bollinger Bands, despite recent underperformance against the S&P 500, although it has outperformed over the longer 3- and 5-year periods.

As of 3 October 2025, the technical trend for Boston Scientific Corp. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by weekly and monthly MACD readings, which are both mildly bearish, and a bearish signal from the weekly Bollinger Bands. The daily moving averages indicate a mildly bullish trend, but this is overshadowed by the overall bearish indicators from the KST and Dow Theory on both weekly and monthly time frames. <BR><BR>In terms of performance, Boston Scientific has underperformed the S&P 500 over the past week and month, with returns of -0.35% and -9.81% compared to the S&P 500's 1.09% and 4.15%, respectively. However, it has outperformed the benchmark over longer periods, such as the 3-year and 5-year returns.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Healthy long term growth as Net Sales has grown by an annual rate of 12.73%

  • OPERATING CASH FLOW(Y) Highest at USD 4,285 MM
  • ROCE(HY) Highest at 11.71%
  • NET SALES(Q) Highest at USD 5,061 MM
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Retailing

stock-summary
Market cap

USD 188,709 Million (Large Cap)

stock-summary
P/E

86.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

5,509.01%

stock-summary
Debt Equity

0.48

stock-summary
Return on Equity

11.42%

stock-summary
Price to Book

8.42

Revenue and Profits:
Net Sales:
5,061 Million
(Quarterly Results - Jun 2025)
Net Profit:
795 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.92%
0%
-8.92%
6 Months
-4.6%
0%
-4.6%
1 Year
7.57%
0%
7.57%
2 Years
78.42%
0%
78.42%
3 Years
109.7%
0%
109.7%
4 Years
147.64%
0%
147.64%
5 Years
183.99%
0%
183.99%

Boston Scientific Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Boston Scientific Hits Day High with 3.95% Surge, Outperforming S&P 500

Boston Scientific Hits Day High with 3.95% Surge, Outperforming S&P 500

Boston Scientific Corp. has shown significant growth, with a notable intraday high and strong weekly and monthly performance. The company has outperformed the S&P 500 in annual and year-to-date gains. Key financial metrics indicate robust sales growth and high institutional investor support, reflecting its resilience in the industry.

Read More
Boston Scientific Forms Death Cross, Signaling Potential Bearish Trend Ahead

Boston Scientific Forms Death Cross, Signaling Potential Bearish Trend Ahead

Boston Scientific Corp. has recently encountered a Death Cross, indicating a potential shift in market sentiment. While technical indicators suggest a bearish trend, the stock has shown resilience with a one-year performance slightly outperforming the S&P 500. Mixed signals from various indicators suggest a complex market position.

Read More
Boston Scientific Corp. Experiences Evaluation Revision Amidst Market Dynamics and Performance Variability

Boston Scientific Corp. Experiences Evaluation Revision Amidst Market Dynamics and Performance Variability

Boston Scientific Corp. has recently revised its evaluation amid fluctuating market conditions. The stock is priced at $96.70, reflecting volatility over the past year. Performance comparisons with the S&P 500 show mixed results, with notable outperformance over three years but recent underperformance in the last month.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
12.73%
EBIT Growth (5y)
26.06%
EBIT to Interest (avg)
5.69
Debt to EBITDA (avg)
2.84
Net Debt to Equity (avg)
0.47
Sales to Capital Employed (avg)
0.50
Tax Ratio
18.32%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
93.61%
ROCE (avg)
6.99%
ROE (avg)
7.79%
Valuation key factors
Factor
Value
P/E Ratio
86
Industry P/E
Price to Book Value
8.01
EV to EBIT
64.79
EV to EBITDA
44.86
EV to Capital Employed
5.78
EV to Sales
10.73
PEG Ratio
6.37
Dividend Yield
5843.20%
ROCE (Latest)
8.92%
ROE (Latest)
9.28%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 196 Schemes (38.17%)

Foreign Institutions

Held by 565 Foreign Institutions (23.08%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 8.54% vs 2.24% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 18.30% vs 19.57% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,061.00",
          "val2": "4,663.00",
          "chgp": "8.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,258.00",
          "val2": "1,221.00",
          "chgp": "3.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "99.00",
          "val2": "87.00",
          "chgp": "13.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-256.00",
          "val2": "-57.00",
          "chgp": "-349.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "795.00",
          "val2": "672.00",
          "chgp": "18.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "182.20%",
          "val2": "192.20%",
          "chgp": "-1.00%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.61% vs 12.29% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 15.95% vs 128.08% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "16,747.00",
          "val2": "14,240.00",
          "chgp": "17.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,904.00",
          "val2": "3,377.00",
          "chgp": "15.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "387.00",
          "val2": "272.00",
          "chgp": "42.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-32.00",
          "val2": "-71.00",
          "chgp": "54.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,846.00",
          "val2": "1,592.00",
          "chgp": "15.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "157.30%",
          "val2": "153.20%",
          "chgp": "0.41%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
5,061.00
4,663.00
8.54%
Operating Profit (PBDIT) excl Other Income
1,258.00
1,221.00
3.03%
Interest
99.00
87.00
13.79%
Exceptional Items
-256.00
-57.00
-349.12%
Consolidate Net Profit
795.00
672.00
18.30%
Operating Profit Margin (Excl OI)
182.20%
192.20%
-1.00%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 8.54% vs 2.24% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 18.30% vs 19.57% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
16,747.00
14,240.00
17.61%
Operating Profit (PBDIT) excl Other Income
3,904.00
3,377.00
15.61%
Interest
387.00
272.00
42.28%
Exceptional Items
-32.00
-71.00
54.93%
Consolidate Net Profit
1,846.00
1,592.00
15.95%
Operating Profit Margin (Excl OI)
157.30%
153.20%
0.41%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 17.61% vs 12.29% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 15.95% vs 128.08% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Boston Scientific Corp. stock-summary
stock-summary
Boston Scientific Corp.
Retailing
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.
Company Coordinates stock-summary
Company Details
300 BOSTON SCIENTIFIC WAY , MARLBOROUGH MA : 01752-1234
stock-summary
Tel: 1 508 6834000
stock-summary
https://www.bostonscientific.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."